LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical development phase, dedicated to pioneering novel therapies for cancer. Utilizing its proprietary Gammabody platform, the company engineers innovative bispecific antibodies. These antibodies are specifically designed to engage and harness the potent and precise capabilities of gamma delta T cells, aiming to stimulate a robust anti-tumor immune response and ultimately enhance outcomes for individuals battling cancer.
| Date | Est. | Actual | |
|---|---|---|---|
| Nov 6, 2025 | -$0.23 | -$0.27 | Miss |
| Aug 13, 2025 | -$0.28 | -$0.32 | Miss |
| May 14, 2025 | -$0.37 | -$0.13 | Beat |
| Mar 28, 2025 | -$0.32 | -$0.14 | Beat |
| Dec 10, 2024 | -$0.33 | -$0.46 | Miss |
| Aug 20, 2024 | -$0.33 | -$0.31 | Beat |